Strategies that target leukocyte traffic in inflammatory bowel diseases: Recent developments

Current Opinion in Gastroenterology

Volumn 31, Issue 6, 2015, Pages 441-448

  Rivera Nieves, Jesús ^a,b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Colitis; Crohn's; Mucosal addressin cell adhesion molecule 1; Sphingosine 1 phosphate; 4 7 integrin

Indexed keywords

AGENTS USED IN INFLAMMATORY BOWEL DISEASE; ALPHA4BETA7 INTEGRIN; BETA INTEGRIN; CD4 ANTIGEN; CHEMOKINE RECEPTOR; ELDELUMAB; ETROLIZUMAB; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTEGRIN; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; OZANIMOD; PF 00547659; UNCLASSIFIED DRUG; VEDOLIZUMAB; GASTROINTESTINAL AGENT; INDAN DERIVATIVE; MONOCLONAL ANTIBODY; OXADIAZOLE DERIVATIVE;

CELL MIGRATION; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FLOW CYTOMETRY; HOLTER MONITORING; HUMAN; LEUKOCYTE; LUNG FUNCTION TEST; LYMPHOCYTE; LYMPHOCYTE RECIRCULATION; MEMORY T LYMPHOCYTE; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; TARGET CELL; ULCERATIVE COLITIS; UPREGULATION; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTIBODIES, MONOCLONAL, HUMANIZED; GASTROINTESTINAL AGENTS; HUMANS; INDANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTES; MOLECULAR TARGETED THERAPY; NATALIZUMAB; OXADIAZOLES;

EID: 84943599564     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000218     Document Type: Review

References (27)

1. Gebhardt T, Whitney PG, Zaid A, et al. Different patterns of peripheral migration by memory CD4+ and CD8+ T cells. Nature 2011; 477:216-219.
2. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7:678-689.
3. Lacy-Hulbert A, Smith AM, Tissire H, et al. Ulcerative colitis and autoimmunity induced by loss of myeloid alphav integrins. Proc Natl Acad Sci U S A 2007; 104:15823-15828.
4. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol 2007; 25:619-647.
5. Pribila JT, Quale AC, Mueller KL, Shimizu Y. Integrins and T cell-mediated immunity. Annu Rev Immunol 2004; 22:157-180.
6. Travis MA, Reizis B, Melton AC, et al. Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature 2007; 449:361-365.
7. Kinashi T. Intracellular signalling controlling integrin activation in lymphocytes. Nat Rev Immunol 2005; 5:546-559.
8. Humphries JD, Byron A, Humphries MJ. Integrin ligands at a glance. J Cell Sci 2006; 119:3901-3903.
9. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110:673-687.
10. Harris ES, McIntyre TM, Prescott SM, Zimmerman GA. The leukocyte integrins. J Biol Chem 2000; 275:23409-23412.
11. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369:699-710.
12. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369:711-721.
13. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147:618-627; e3.
14. Vermeire S, O'Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014; 384:309-318.
15. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997; 151:97-110.
16. Connor EM, Eppihimer MJ, Morise Z, et al. Expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in acute and chronic inflammation. J Leukoc Biol 1999; 65:349-355.
17. Sikorski EE, Hallmann R, Berg EL, Butcher EC. The Peyer's patch high endothelial receptor for lymphocytes, the mucosal vascular addressin, is induced on a murine endothelial cell line by tumor necrosis factor-alpha and IL-1. J Immunol 1993; 151:5239-5250.
18. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 2006; 6:244-251.
19. Salmi M, Andrew DP, Butcher EC, Jalkanen S. Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans: dissection of the molecular mechanisms. J Exp Med 1995; 181:137-149.
20. Pullen N, Molloy E, Carter D, et al. Pharmacological characterization of PF-00547659, an antihuman MAdCAM monoclonal antibody. Br J Pharmacol 2009; 157:281-293.
21. Reinisch W, Sandborn W, Danese S, et al. 901a A randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of anti- MAdCAM Antibody PF-00547659 (PF) in patients with moderate to severe ulcerative colitis: results of the TURANDOT study. Gastroenterology 2015; 148:S-1193.
22. Sandborn W, Lee SD, Tarabar D, et al. 825 anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease: results of the OPERA study. Gastroenterology 2015; 148:S-162.
23. Wendt E, Keshav S. CCR9 antagonism: potential in the treatment of inflammatory bowel disease. Clin Exp Gastroenterol 2015; 8:119-130.
24. Mayer L, Sandborn WJ, Stepanov Y, et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut 2014; 63:442-450.
25. Sandborn WJ, Rutgeerts PJ, Colombel J-F, et al. 827 Phase IIA, randomized, placebo-controlled evaluation of the efficacy and safety of induction therapy with eldelumab (anti-IP-10 antibody; BMS-936557) in patients with active Crohn's disease. Gastroenterology 2015; 148:S-162-S-163.
26. Masopust D, Choo D, Vezys V, et al. Dynamic T cell migration program provides resident memory within intestinal epithelium. J Exp Med 2010; 207:553-564.
27. Sandborn W, Feagan BG, Wolf DC, et al. 445 The TOUCHSTONE study: a randomized, double-blind, placebo-controlled induction trial of an oral S1P receptor modulator (RPC1063) in moderate to severe ulcerative colitis. Gastroenterology 2015; 148:S-93.